体内研究 (In Vivo) |
Losulazine (1-5 mg/kg;腹腔注射;每日给药;连续 13 天) 对成年雄性 Wistar 大鼠的睾丸类固醇生成及附属性腺功能呈剂量依赖性双相作用。 Losulazine (4-32 mg/kg;口服;每日给药;持续 1 年) 在雄性 Sprague-Dawley 大鼠中,可诱导剂量依赖性的可逆性生育力下降、剂量依赖性的体重增长和食物消耗量降低、与剂量无关的轻微至轻度睾丸损伤,以及相对脏器重量增加。 Losulazine (10 mg/kg;口服;每日给药,持续 15-27 天,单次剂量) 通过下丘脑儿茶酚胺耗竭和随后的高催乳素血症,导致雌性 Sprague-Dawley 大鼠完全无发情。 Losulazine (2-8 mg/kg;口服;每日给药) 呈剂量依赖性地损害 Sprague-Dawley 大鼠的生育能力与生殖功能。 Losulazine (2.5-10 mg/kg;腹腔注射;单次给药) 可使大鼠血脑屏障外的脑区和垂体区儿茶酚胺显著且持续耗竭,同时使血脑屏障保护区域的多巴胺出现轻微且短暂的降低,并短暂升高血浆催乳素和 α-黑素细胞刺激素浓度。 Losulazine (2.5 mg/kg;腹腔注射;单次给药;每日一次;连续 12 天) 可导致雌性大鼠发情周期紊乱,在无血脑屏障的脑区和垂体区域持续耗竭儿茶酚胺且无耐受性,同时在纹状体产生累积性多巴胺耗竭作用,但对中枢 5-羟色胺能神经元无影响。 Losulazine 可通过调节交感神经活性在清醒猴中发挥降压作用,且不会引发直立性低血压。
| Animal Model: |
Wistar rats (adult male, 120-140 days old, 145-170 g) |
| Dosage: |
1; 2; 5 mg/kg |
| Administration: |
i.p.; daily; 13 days |
| Result: |
Significantly increased relative weights of total prostate, ventral prostate, and seminal vesicles at all doses. Significantly increased relative coagulating gland weight only at 2 mg/kg. Caused no significant changes in relative testes or epididymis weights. Significantly increased testicular 3β-hydroxysteroid dehydrogenase (HSD) and 17β-HSD activity, while reducing testicular cholesterol content. Significantly increased testicular acid phosphatase activity, ventral prostate acid phosphatase activity, and fructose content in seminal vesicles at 1 and 2 mg/kg. Significantly reduced testicular acid phosphatase activity, and fructose content in seminal vesicles at 5 mg/kg.
|
| Animal Model: |
Sprague-Dawley rats (male, 220-358 g) |
| Dosage: |
4; 8; 16; 32 mg/kg |
| Administration: |
p.o.; daily; 1 year or 30 weeks |
| Result: |
Induced dosage-dependent ptosis, somnolence, fecal softening/decreased food consumption. Caused statistically significant decreased body weight gain in the 16 and 32 mg/kg; retarded weight gain occurred only in the second half of the study in the 8 mg/kg group. Decreased urinary pH in the 8, 16, and 32 mg/kg/day groups; no biologically significant changes in urinalysis values between treated and control rats. Lowered luteinizing hormone levels significantly to 3.3 ng/mL in the 32 mg/kg/day group; no significant changes in prolactin or testosterone levels were seen in any treated group. Increased relative spleen, heart, and adrenal weights in all treated groups. Increased relative brain weights. Produced dosage- and time-dependent decreased conception rates during treatment. Promoted significant fertility recovery within 5 weeks of drug withdrawal, with no significant differences between treated and control groups. Increased incidence of epididymal degenerate cells in all groups. |
| Animal Model: |
Sprague-Dawley rats (female, 210 to 270 g) with reproductive dysfunction |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose or daily for 15, 16, 27 days |
| Result: |
Reduced hypothalamic dopamine, norepinephrine, and epinephrine. Depleted hypothalamic dopamine, norepinephrine, and epinephrine. Reduced uterus-cervix-vagina weights and caused vaginal mucosa attenuation with vacuolated surface epithelium, and caused splenic congestion. Did not affect serum follicle-stimulating hormone, luteinizing hormone, and progesterone levels. Induced partial ptosis and fecal softening as clinical signs. |
| Animal Model: |
Sprague-Dawley (Upj: TUC(SD)spf; male and female; 8-10 weeks of age, males 220-361 g, females 209-270 g at study start) |
| Dosage: |
2; 4; 8 mg/kg |
| Administration: |
p.o.; daily |
| Result: |
Caused ptosis in all treated rats. Increased mean body weight gain in treated females after 14 days of treatment. Disrupted estrous cycles in treated females, with significantly more days in diestrus, fewer days in proestrus, estrus, metestrus, and fewer total cycles over 14 days of treatment. Decreased conception rates dose-dependently. Prolonged mean gestation lengths in treated females given 4 and 8 mg/kg. Induced moderate to severe testicular tubular necrosis, spermatic giant cell formation, and tubular atrophy in treated males. Caused exudative prostatitis and ampullary gland sperm granulomas in 2, 4, 8 mg/kg groups. Delayed functional development. Reduced negative geotaxis response scores and prolonged response times at multiple time points in treated groups. Impaired reproductive ability of F1 offspring. |
| Animal Model: |
Long-Evans rats (adult male, 200-225 g) |
| Dosage: |
2.5; 5; 10 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Produced maximal depletion of dopamine and norepinephrine in the median eminence, intermediate lobe, and neural lobe. Reduced dopamine concentrations in the striatum and nucleus accumbens. Reduced dopamine levels in the dorsomedial nucleus. Failed to reduce norepinephrine concentrations in the dorsomedial nucleus. Caused no effect on 5-hydroxytryptamine concentrations in the dorsomedial nucleus. Increased plasma prolactin and α-melanocyte-stimulating hormone levels. |
| Animal Model: |
Long-Evans (adult female, 200-225 g, regular estrous cycles prior to treatment) |
| Dosage: |
2.5 mg/kg |
| Administration: |
i.p.; single dose; or daily for 12 days |
| Result: |
Caused rats to become acyclic with persistent diestrous-like smears by 6-7 days of chronic treatment. Produced 80-90% dopamine depletion and 50-70% norepinephrine depletion in the median eminence, intermediate lobe, and neural lobe with both acute and chronic doses, with no tolerance development. Caused greater dopamine depletion in the striatum with chronic administration than acute administration, with a nonsignificant trend toward greater depletion in the nucleus accumbens. Produced modest decreases in dopamine and norepinephrine concentrations in the dorsomedial nucleus with both acute and chronic doses, with no effect on 5-hydroxytryptamine concentrations in this region. |
|